BMEA Stock — Biomea Fusion Inc.: Cash, EV, Pipeline

What they do

We are a clinical‑stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. The company was founded in 2017 with the goal of creating targeted treatments built through expertise in chemistry and a deep understanding of metabolic biology.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.57

Market cap

$41.1M

Cash

$34.8M

Enterprise value

$6.3M

Balance sheet

Cash	$34.8M
Debt	$0.0M
Net cash	$34.8M
Enterprise value	$6.3M
Basic shares	72.5M shares
Fully diluted shares	124.8M shares
Fully diluted market cap	$71.2M
Cash per share	$0.48
Quarterly burn	$10.0M
Cash runway	3.5 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

72.5M

Pre-funded warrants

0.0M

Options

13.2M

RSUs

0.8M

Warrants

37.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.3M

FDSO

124.8M

Cap table as of 2026-06-30.

Price history

Loading BMEA daily closes…

Loading price history…

Next catalyst

icovamenib · Est. Feb 14, 2027 · quarter midpoint · guided in 8 wks

Recently reported

BMF-650 Phase 1 Negative · 2026-10-13

GLP-131

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	icovamenib COVALENT-211 Phase II 26-week primary endpoint topline in insulin-deficient type 2 diabetes · NCT07502495	Phase 2	insulin-deficient type 2 diabetes	Q1 2027
Apr 12 - May 24 in 5 mo	icovamenib 100mg	Phase 2	Type 2 Diabetes	—
GUIDEDEst. May 16, 2027 in 5 mo quarter midpoint	icovamenib COVALENT-212 Phase II 26-week primary endpoint topline · NCT07502508	Phase 2	Not disclosed	Q2 2027
Jul 13 - Aug 24 in 8 mo	icovamenib 100 mg	Phase 2	Type 2 Diabetes	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Icovamenib

Phase 2 · Active Modality: oral covalent small molecule

Target menin

Indications

Type 2 diabetes (Phase 2)
Type 1 diabetes (Phase 2)
Obesity (Stage not disclosed)

Catalysts

— Q4 2026

Status note Lead program; oral covalent menin inhibitor. COVALENT-112 T1D topline reported Apr 2026; only the two T2D Phase 2 trials (COVALENT-211/212) listed as ongoing as of Jun 30, 2026. Oncology exploration explicitly discontinued; obesity impact under investigation (preclinical).

BMF-650

Phase 1 · Active Modality: oral small molecule

Target GLP-1 receptor

Indications

Obesity (Phase 1)

Catalysts

— Q3 2026

Status note Next-generation oral GLP-1 receptor agonist; IND cleared Sep 2025; Phase I GLP-131 trial ongoing.

BMF-500

Stage not disclosed · Active Modality: covalent small molecule

Target FLT3

Indications

Oncology (indication not stated) (Stage not disclosed)

Status note Covalent FLT3 inhibitor. Internal oncology work deprioritized (icovamenib oncology studies discontinued); company plans to explore partnerships to advance BMF-500 while concentrating internal resources on metabolic disorders.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	icovamenib 100mg
Lead indication	Type 2 Diabetes
Lead phase	Phase 2
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07502495	Phase 2	Active, not recruiting	Sponsor	BMEA	—	Type 2 Diabetes	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
NCT07502508	Phase 2	Recruiting	Sponsor	BMEA	—	Type 2 Diabetes	Q2 2027 Est. May 16, 2027 · quarter midpoint
NCT05918692	Phase 1	Active, not recruiting	Sponsor	BMEA	—	Acute Myeloid Leukemia	—
NCT07223216	Phase 1	Active, not recruiting	Sponsor	BMEA	—	Obesity	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Biomea Fusion Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Aisling Capital	2,048,757	no change	0.64%	2026-08-13
ADAR1 Capital Management	43,420	no change	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

BMEA — Biomea Fusion Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

BMEA — Biomea Fusion Inc.